Citizens Jmp Lowers GH Research (NASDAQ:GHRS) Price Target to $39.00

GH Research (NASDAQ:GHRS) had its target price lowered by equities research analysts at Citizens Jmp from $42.00 to $39.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 75.60% from the company’s previous close.

A number of other brokerages have also recently issued reports on GHRS. Royal Bank Of Canada raised their target price on shares of GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Needham & Company LLC raised their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Guggenheim set a $34.00 target price on shares of GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. HC Wainwright increased their target price on GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of GH Research in a research report on Friday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.75.

GH Research Trading Up 1.5%

GHRS stock opened at $22.21 on Friday. The firm has a market cap of $1.38 billion, a P/E ratio of -27.76 and a beta of 1.27. GH Research has a 12-month low of $9.52 and a 12-month high of $24.66. The stock’s 50 day simple moving average is $17.03 and its 200 day simple moving average is $15.49.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). On average, research analysts forecast that GH Research will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

Several large investors have recently made changes to their positions in GHRS. Barclays PLC increased its stake in shares of GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares during the period. North Star Investment Management Corp. acquired a new stake in shares of GH Research in the first quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of GH Research in the fourth quarter valued at approximately $38,000. Osaic Holdings Inc. increased its stake in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in shares of GH Research in the second quarter valued at approximately $79,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.